药品的自付费用能否有助于使欧盟的医疗保健系统减少受到政治影响？ - Suppr

Suppr

超能文献

Could co-payments on drugs help to make EU health care systems less open to political influence?

作者信息

Garattini Livio, van de Vooren Katelijne

出版信息

Eur J Health Econ. 2013 Oct;14(5):709-13. doi: 10.1007/s10198-012-0428-1.

DOI:10.1007/s10198-012-0428-1

PMID:22961231

Abstract

摘要

相似文献

Could co-payments on drugs help to make EU health care systems less open to political influence?

Eur J Health Econ. 2013 Oct;14(5):709-13. doi: 10.1007/s10198-012-0428-1.

Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay.

Int J Pharm Pract. 2010 Dec;18(6):332-40. doi: 10.1111/j.2042-7174.2010.00063.x. Epub 2010 Oct 5.

Diversity and dynamics of patient cost-sharing for physicians' and hospital services in the 27 European Union countries.

Eur J Public Health. 2011 Oct;21(5):585-90. doi: 10.1093/eurpub/ckq139. Epub 2010 Sep 30.

The cost of prescription medicines to patients.

Health Policy. 2000 Jun;52(2):129-45. doi: 10.1016/s0168-8510(00)00066-x.

Relationship between high cost sharing and adverse outcomes: a truism that's tough to prove.

Am J Manag Care. 2010 Apr;16(4):287-9.

Solidarity as a Political Determinant of Health: Insights from EU Competition Policy.

J Health Polit Policy Law. 2024 Oct 1;49(5):783-803. doi: 10.1215/03616878-11257016.

The future of prescription drug cost-sharing: real progress or dropped opportunity?

J Manag Care Pharm. 2008 Jan-Feb;14(1):70-82. doi: 10.18553/jmcp.2008.14.1.70.

How to combat Pharma's costly coupon programs.

Manag Care. 2012 May;21(5):22-6.

Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs.

JAMA. 2018 Mar 13;319(10):1045-1047. doi: 10.1001/jama.2018.0102.

Employer drug benefit plans and spending on prescription drugs.

JAMA. 2002 Oct 9;288(14):1733-9. doi: 10.1001/jama.288.14.1733.

引用本文的文献

Competition in health markets: is something rotten?

J R Soc Med. 2019 Jan;112(1):6-10. doi: 10.1177/0141076818816935. Epub 2018 Dec 3.

European Medicines Agency: leave the UK but remain the same.

J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.

Is the US "leading from behind" on health policy?

Eur J Health Econ. 2014 Mar;15(2):113-6. doi: 10.1007/s10198-013-0548-2. Epub 2013 Dec 10.

本文引用的文献

Ethics for end-of-life treatments: metastatic colorectal cancer is one example.

Health Policy. 2013 Jan;109(1):97-103. doi: 10.1016/j.healthpol.2012.08.017. Epub 2012 Sep 14.

HPV vaccination for boys? Talking economic sense.

J Sex Med. 2012 Aug;9(8):2195-6. doi: 10.1111/j.1743-6109.2012.02828.x. Epub 2012 Jul 3.

Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.

PLoS One. 2012;7(5):e34974. doi: 10.1371/journal.pone.0034974. Epub 2012 May 9.

Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?

Eur J Health Econ. 2012 Feb;13(1):1-5. doi: 10.1007/s10198-011-0353-8.

France: Health system review.

Health Syst Transit. 2010;12(6):1-291, xxi-xxii.

Effects of reference pricing in pharmaceutical markets: a review.

Pharmacoeconomics. 2011 Jan;29(1):17-33. doi: 10.2165/11537860-000000000-00000.

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.

Eur J Health Econ. 2011 Jun;12(3):263-71. doi: 10.1007/s10198-010-0274-y. Epub 2010 Aug 28.

Increased ambulatory care copayments and hospitalizations among the elderly.

N Engl J Med. 2010 Jan 28;362(4):320-8. doi: 10.1056/NEJMsa0904533.

The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany.

Eur J Health Econ. 2010 Jun;11(3):267-77. doi: 10.1007/s10198-009-0172-3. Epub 2009 Jul 29.

What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Int J Equity Health. 2008 May 2;7:12. doi: 10.1186/1475-9276-7-12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Could co-payments on drugs help to make EU health care systems less open to political influence?

Eur J Health Econ. 2013 Oct;14(5):709-13. doi: 10.1007/s10198-012-0428-1.

Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay.

Int J Pharm Pract. 2010 Dec;18(6):332-40. doi: 10.1111/j.2042-7174.2010.00063.x. Epub 2010 Oct 5.

Diversity and dynamics of patient cost-sharing for physicians' and hospital services in the 27 European Union countries.

Eur J Public Health. 2011 Oct;21(5):585-90. doi: 10.1093/eurpub/ckq139. Epub 2010 Sep 30.

The cost of prescription medicines to patients.

Health Policy. 2000 Jun;52(2):129-45. doi: 10.1016/s0168-8510(00)00066-x.

Relationship between high cost sharing and adverse outcomes: a truism that's tough to prove.

Am J Manag Care. 2010 Apr;16(4):287-9.

Solidarity as a Political Determinant of Health: Insights from EU Competition Policy.

J Health Polit Policy Law. 2024 Oct 1;49(5):783-803. doi: 10.1215/03616878-11257016.

The future of prescription drug cost-sharing: real progress or dropped opportunity?

J Manag Care Pharm. 2008 Jan-Feb;14(1):70-82. doi: 10.18553/jmcp.2008.14.1.70.

How to combat Pharma's costly coupon programs.

Manag Care. 2012 May;21(5):22-6.

Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs.

JAMA. 2018 Mar 13;319(10):1045-1047. doi: 10.1001/jama.2018.0102.

Employer drug benefit plans and spending on prescription drugs.

JAMA. 2002 Oct 9;288(14):1733-9. doi: 10.1001/jama.288.14.1733.

引用本文的文献

Competition in health markets: is something rotten?

J R Soc Med. 2019 Jan;112(1):6-10. doi: 10.1177/0141076818816935. Epub 2018 Dec 3.

European Medicines Agency: leave the UK but remain the same.

J R Soc Med. 2016 Sep;109(9):324-5. doi: 10.1177/0141076816663559.

Is the US "leading from behind" on health policy?

Eur J Health Econ. 2014 Mar;15(2):113-6. doi: 10.1007/s10198-013-0548-2. Epub 2013 Dec 10.

本文引用的文献

Ethics for end-of-life treatments: metastatic colorectal cancer is one example.

Health Policy. 2013 Jan;109(1):97-103. doi: 10.1016/j.healthpol.2012.08.017. Epub 2012 Sep 14.

HPV vaccination for boys? Talking economic sense.

J Sex Med. 2012 Aug;9(8):2195-6. doi: 10.1111/j.1743-6109.2012.02828.x. Epub 2012 Jul 3.

Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.

PLoS One. 2012;7(5):e34974. doi: 10.1371/journal.pone.0034974. Epub 2012 May 9.

Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?

Eur J Health Econ. 2012 Feb;13(1):1-5. doi: 10.1007/s10198-011-0353-8.

France: Health system review.

Health Syst Transit. 2010;12(6):1-291, xxi-xxii.

Effects of reference pricing in pharmaceutical markets: a review.

Pharmacoeconomics. 2011 Jan;29(1):17-33. doi: 10.2165/11537860-000000000-00000.

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment.

Eur J Health Econ. 2011 Jun;12(3):263-71. doi: 10.1007/s10198-010-0274-y. Epub 2010 Aug 28.

Increased ambulatory care copayments and hospitalizations among the elderly.

N Engl J Med. 2010 Jan 28;362(4):320-8. doi: 10.1056/NEJMsa0904533.

The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany.

Eur J Health Econ. 2010 Jun;11(3):267-77. doi: 10.1007/s10198-009-0172-3. Epub 2009 Jul 29.

What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Int J Equity Health. 2008 May 2;7:12. doi: 10.1186/1475-9276-7-12.